Team:Paris Bettencourt
From 2013.igem.org
(Difference between revisions)
Line 125: | Line 125: | ||
height:283px; | height:283px; | ||
font-size:22px; | font-size:22px; | ||
- | background:rgb( | + | background:rgb(255,255,255); |
- | color: | + | color:black; |
border-radius:7px; | border-radius:7px; | ||
overflow:hidden; | overflow:hidden; | ||
Line 291: | Line 291: | ||
<a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Facts" title="TB Facts"> | <a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Facts" title="TB Facts"> | ||
<div class="subpanel5"> | <div class="subpanel5"> | ||
- | <center><img src="https://static.igem.org/mediawiki/2013/ | + | <img class="narrowimg" src="https://static.igem.org/mediawiki/2013/f/f9/PB_TBfacts2.png" width="354px" height="156px"/> |
+ | <div style="position:relative;bottom:258px"> | ||
+ | <center><img src="https://static.igem.org/mediawiki/2013/6/69/PB_logoTBfacts.png" style="height:50px;margin-top:10px;margin-bottom:20px;"/></center> | ||
<div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | <div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | ||
TB Facts | TB Facts | ||
+ | </div> | ||
</div> | </div> | ||
</a> | </a> | ||
<a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_France" title="TB in France"> | <a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_France" title="TB in France"> | ||
<div class="subpanel5"> | <div class="subpanel5"> | ||
+ | <img class="narrowimg" src="https://static.igem.org/mediawiki/2013/3/39/PB_TBinFrance.png" width="354px" height="156px"/> | ||
+ | <div style="position:relative;bottom:258px"> | ||
<center><img src="https://static.igem.org/mediawiki/2013/e/ec/PB_TBinfrance.png" style="height:50px;margin-top:10px;margin-bottom:20px;"/></center> | <center><img src="https://static.igem.org/mediawiki/2013/e/ec/PB_TBinfrance.png" style="height:50px;margin-top:10px;margin-bottom:20px;"/></center> | ||
<div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | <div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | ||
TB in France | TB in France | ||
- | + | </div> | |
+ | </div> | ||
</a> | </a> | ||
<a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Gallery" title="TB Gallery"> | <a class="subpanel5" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Gallery" title="TB Gallery"> | ||
Line 314: | Line 320: | ||
<a class="subpanel7" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/Gender_Study" title="Gender Study"> | <a class="subpanel7" href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/Gender_Study" title="Gender Study"> | ||
<div class="subpanel7"> | <div class="subpanel7"> | ||
- | <center><img src="https://static.igem.org/mediawiki/2013/ | + | <img class="narrowimg" src="https://static.igem.org/mediawiki/2013/8/8c/Gender.png" width="354px" height="283px"/> |
+ | <div style="position:relative;bottom:258px"> | ||
+ | <center><img src="https://static.igem.org/mediawiki/2013/d/da/PB_logogender.png" style="height:60px;margin-top:10px;margin-bottom:10px;"/></center> | ||
<div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | <div style="width:60%;margin-left:20%;margin-bottom:20px;"><hr></div> | ||
Gender Study | Gender Study | ||
+ | </div> | ||
</div> | </div> | ||
</a> | </a> |
Revision as of 01:59, 5 October 2013
![](https://static.igem.org/mediawiki/2013/c/c8/PB_frontpagebanner.png)
![](https://static.igem.org/mediawiki/2013/7/7d/PB_Banner_Lines2.gif)
![](https://static.igem.org/mediawiki/2013/3/3a/PB_logoParis.gif)
FIGHT TUBERCULOSIS WITH MODERN WEAPONS
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that affects nearly two billion people around the world. On this website we present four new ways to use the power of synthetic biology in the fight against TB.
A biosensor that detects the presence of sequence specific antibiotic resistance genes.
A safe and specific high-throughput drug screening method that targets essential mycobacterial metabolic proteins.
A phage system with low fitness cost producing sRNA, which inhibit the synthesis of antibiotic resistance proteins.
Infiltrate macrophages with an E.coli producing TDMH, an enzyme that will lyse the Mycobacteria cell wall.
![](https://static.igem.org/mediawiki/2013/a/a8/PB_DetectNarrow.jpg)
![](https://static.igem.org/mediawiki/2013/0/0b/PB_detecticon.gif)
![](https://static.igem.org/mediawiki/2013/e/e2/PB_TargetNarrow.jpg)
![](https://static.igem.org/mediawiki/2013/1/11/PB_TargetIcon.gif)
![](https://static.igem.org/mediawiki/2013/2/21/PB_InfiltrateNarrow.jpg)
![](https://static.igem.org/mediawiki/2013/6/6c/PB_infiltrate.gif)
![](https://static.igem.org/mediawiki/2013/4/42/PB_SabotageNarrow.jpg)
![](https://static.igem.org/mediawiki/2013/8/81/PB_sabotageicone.gif)
![](https://static.igem.org/mediawiki/2013/d/d5/PB_handresults.gif)